Compare NVCR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVCR | CDNA |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2015 | 2007 |
| Metric | NVCR | CDNA |
|---|---|---|
| Price | $17.90 | $21.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $28.08 | $28.00 |
| AVG Volume (30 Days) | ★ 1.8M | 652.5K |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.79 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $655,353,000.00 | $48,324,000.00 |
| Revenue This Year | $7.72 | $16.01 |
| Revenue Next Year | $6.74 | $11.31 |
| P/E Ratio | ★ N/A | $429.80 |
| Revenue Growth | 8.28 | ★ 18.93 |
| 52 Week Low | $9.82 | $10.96 |
| 52 Week High | $20.05 | $23.24 |
| Indicator | NVCR | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 66.10 | 59.06 |
| Support Level | $12.48 | $15.80 |
| Resistance Level | $18.92 | $22.89 |
| Average True Range (ATR) | 0.90 | 1.00 |
| MACD | -0.08 | -0.06 |
| Stochastic Oscillator | 70.74 | 76.54 |
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.